Abstract:Objective Dysregulated immune responses are the cause of IBDs. Studies in mice and humans suggest a central role of interleukin (IL)-23-producing mononuclear phagocytes in disease pathogenesis. Mechanistic insights into the regulation of IL-23 are prerequisite for selective IL-23 targeting therapies as part of personalised medicine. Design We performed transcriptomic analysis to investigate IL-23 expression in human mononuclear phagocytes and peripheral blood mononuclear cells. We investigated the regulation of IL-23 expression and used single-cell RNA sequencing to derive a transcriptomic signature of hyperinflammatory monocytes. Using gene network correlation analysis, we deconvolved this signature into components associated with homeostasis and inflammation in patient biopsy samples. Results We characterised monocyte subsets of healthy individuals and patients with IBD that express IL-23. We identified autosensing and paracrine sensing of IL-1α/IL-1β and IL-10 as key cytokines that control IL-23-producing monocytes. Whereas Mendelian genetic defects in IL-10 receptor signalling induced IL-23 secretion after lipopolysaccharide stimulation, whole bacteria exposure induced IL-23 production in controls via acquired IL-10 signalling resistance. We found a transcriptional signature of IL-23-producing inflammatory monocytes that predicted both disease and resistance to antitumour necrosis factor (TNF) therapy and differentiated that from an IL-23-associated lymphocyte differentiation signature that was present in homeostasis and in disease. Conclusion Our work identifies IL-10 and IL-1 as critical regulators of monocyte IL-23 production. We differentiate homeostatic IL-23 production from hyperinflammation-associated IL-23 production in patients with severe ulcerating active Crohn’s disease and anti-TNF treatment non-responsiveness. Altogether, we identify subgroups of patients with IBD that might benefit from IL-23p19 and/or IL-1α/IL-1β-targeting therapies upstream of IL-23.

Interleukin-23, its Receptor and Inflammatory Bowel Disease

Interleukin-17 and Inflammatory Bowel Disease: a 2-Sample Mendelian Randomization Study

The Expression of Interleukin-23 Receptor and Interleukin-17a in Patients with Inflammatory Bowel Disease and its Clinical Significance

Synergy of IL-23 and Th17 Cytokines: New Light on Inflammatory Bowel Disease

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

A Deep View of the Biological Property of Interleukin-33 and Its Dysfunction in the Gut

High Intestinal and Systemic Levels of Interleukin-23/T-Helper 17 Pathway in Chinese Patients with Inflammatory Bowel Disease

IL-33 and IL-18 in Inflammatory Bowel Disease Etiology and Microbial Interactions

IL-23 plays a key role in Helicobacter hepaticus–induced T cell–dependent colitis

Expression and significance of interleukin-12 family cytokines in peripheral blood of patients with inflammatory bowel disease

Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease

The role of IL-19, IL-24, IL-21 and IL-33 in intestinal mucosa of inflammatory bowel disease: A narrative review

Interleukin-23 Receptor Genetic Polymorphisms and Crohn’s Disease Susceptibility: a Meta-Analysis

A new target for the treatment of inflammatory bowel disease: Interleukin-37

Research Progress of Th17 Cells and IL-23 in Inflammatory Bowel Disease

Leukocyte immunoglobulin-like receptor A3 is increased in IBD patients and functions as an anti-inflammatory modulator

Role of the IL23/IL17 Pathway in Crohn's Disease

Interleukin-35 -Producing B Cells Rescues Inflammatory Bowel Disease in a Mouse Model Via STAT3 Phosphorylation and Intestinal Microbiota Modification

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance

Th17,Th17 Cytokines and Inflammatory Bowel Disease

Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity